Drug Combination Details
General Information of the Combination (ID: C20036) | |||||
---|---|---|---|---|---|
Name | Metformin NP Info | + | Sorafenib Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Phase 2 | [1] | ||
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [2] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [3] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Experimental
Result(s) |
This study demonstrated cytotoxic effects of metformin and synergistic antitumor effects of sorafenib. | |||||
Experiment 2 Reporting the Effect of This Combination | [2] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | HTh74 | CVCL_6288 | Thyroid gland anaplastic carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Sorafenib and metformin synergistically decreased the proliferation of ATC cell lines and the outgrowth of their derived cancer stem cells. |
![](/sites/default/files/kegg_pathway/hsa04060+3553.png)
![](/sites/default/files/kegg_pathway/hsa04668+3569.png)
![](/sites/default/files/kegg_pathway/hsa04140+84557.png)
![](/sites/default/files/kegg_pathway/hsa04152+5563.png)
![](/sites/default/files/kegg_pathway/hsa04668+7124.png)
![](/sites/default/files/kegg_pathway/hsa04115+7157.png)